Eli Lilly’s antibody-drug was found to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, the company said Thursday.
The drug is being evaluated as part of a Phase 3 trial involving 965 participants that were conducted in part by the National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network...
See the whole story on Fox Business right here,